

Representative Regeneron U.S. Product Related Patents

In accordance with Section 287(a) of Title 35 of the United States Code, below is a list of certain Regeneron products and corresponding representative U.S. patents associated with the relevant product. This list represents a subset of Regeneron’s product patent rights. Additional patents may be granted or pending in the U.S. and in other countries. Other Regeneron products not listed here may be protected by one or more patents in the U.S. and other countries.

EYLEA® (aflibercept) Injection
For Intravitreal Injection

U.S. 8,092,803
 U.S. 9,254,338*
 U.S. 9,669,069*
 U.S. 10,130,681*
 U.S. 10,828,345
 U.S. 11,066,458
 U.S. 11,084,865
 U.S. 11,559,564
 U.S. 11,707,506
 U.S. 11,730,794
 U.S. 11,732,024

EYLEA® HD (aflibercept) Injection 8mg
For Intravitreal Injection

U.S. 9,254,338*
 U.S. 10,130,681*
 U.S. 10,828,345
 U.S. 11,066,458
 U.S. 11,084,865
 U.S. 11,103,552

*One or more claims in the indicated patents has been found invalid or unpatentable by a court or patent office, the decisions of which are subject to appeal.